Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...

Pfizer's Q3 consensus estimate is likely to be exceeded. Despite the underperformance over the past two months, see why PFE ...

STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...